2022 Volume 11 Issue 3 Pages 140-147
Hematopoietic stem cell transplantation for malignant lymphoma is performed to improve prognosis of the patients with relapsed/refractory disease or untreated patients with poor prognostic features. High-dose therapy followed by autologous hematopoietic stem cell transplantation (ASCT) for the patients with chemosensitive relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is given based on the result of a randomized phase 3 trial. Salvage chemotherapy followed by ASCT is still an effective salvage strategy in the patients with late relapse after first-line therapy; however, the probability of achieving response to salvage chemotherapy is very limited in the patients with early relapse. Such a conventional salvage treatment is likely to be replaced by CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) in the patients with DLBCL with early relapse. Allogeneic transplantation has been an option for third-line therapy for DLBCL and classic Hodgkin lymphoma (cHL). In DLBCL, the role of allogeneic transplantation is decreasing with the introduction of CAR-T. In cHL, higher risk of immune-related complications after allogeneic transplantation followed by anti-PD-1 antibody is recognized as an emerging challenge.
